Examiner: REGLAS, GILLIAN CHELSEA

Tech Center 1600 • Art Units: 1632

This examiner grants 30% of resolved cases

Analysis

Gillian Chelsea Reglas is an examiner in Tech Center 1600 and Art Unit 1632. She has 63 resolved cases in her record. The allowance rate for these cases is 30.2 percent. This 30.2 percent rate provides a baseline for applicants to understand the frequency of patent grants in her docket. With 63 resolved cases, the data offers a perspective on her examination history.

The interview lift is 41.5 percent. This 41.5 percent figure shows the increase in the likelihood of allowance when an interview is conducted compared to the overall allowance rate. Practitioners in Art Unit 1632 can use this lift to inform their strategy. The median days to allowance is 1451. This 1451-day period represents the time typically required to reach a grant. Stakeholders can use the 1451-day metric and the 30.2 percent allowance rate to plan their prosecution timelines in Tech Center 1600.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

30.2%

Allow Rate

-29.8% vs TC avg

107

Total Applications

+41.5%

Interview Lift

1451

Avg Prosecution Days

Based on 63 resolved cases, 2023–2026

Rejection Statute Breakdown

5.4%

§101 Eligibility

14.8%

§102 Novelty

41.2%

§103 Obviousness

30.5%

§112 Clarity

Currently Pending Office Actions

App #	Title	Status	Assignee
17419234	SYNTHETIC MOLECULAR FEEDBACK CIRCUITS AND METHODS OF USING THE SAME	Final Rejection	The Regents of the University of California
18021156	EX VIVO BRAIN TUMOR MODEL	Non-Final OA	Massachusetts Institute of Technology
17772539	PROTEASE SWITCH FOR DUAL TARGETS CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY	Final Rejection	THE TEXAS A&M UNIVERSITY SYSTEM
18310048	COMPOSITIONS AND METHODS FOR CELLULAR COMPONENT TRANSFER THERAPY	Non-Final OA	The Johns Hopkins University
17434186	ENGINEERED IMMUNE CELLS	Final Rejection	NATIONAL UNIVERSITY OF SINGAPORE
17904381	METHOD FOR PREPARING FIBROSIS-ENCAPSULATED TUMOROID, AND USE THEREOF	Final Rejection	INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
17421908	COMPOSITIONS AND METHODS FOR TREATMENT OF A MALABSORPTIVE DISORDER	Non-Final OA	CHILDREN'S HOSPITAL MEDICAL CENTER
17965656	COMPOSITIONS FOR PREVENTING OR TREATING DIABETIC SKIN DISEASE COMPRISING EXOSOME-DERIVED FROM THROMBIN-TREATED STEM CELL	Non-Final OA	SAMSUNG LIFE PUBLIC WELFARE FOUNDATION

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy